Paper Details

  1. Home
  2. Paper Details

Targeted Therapy in Thyroid Cancer: State of the Art.

Author: AgateL, BotticiV, CappagliV, CiampiR, EliseiR, GianiC, LorussoL, MatroneA, MolinaroE, PieruzziL, PuleoL, RomeiC, ValerioL, ViolaD

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Tyrosine kinase inhibitors (TKIs) represent a promising therapeutic option for advanced thyroid cancer, with sorafenib and lenvatinib for differentiated and poorly differentiated thyroid cancer, and vandetanib and cabozantinib for medullary thyroid cancer.
Paper Details　
Original Abstract of the Article :
Thyroid cancer typically has a good outcome following standard treatments, which include surgery, radioactive iodine ablation for differentiated tumours and treatment with thyrotropine hormone-suppressive levothyroxine. Thyroid cancers that persist or recur following these therapies have a poorer pr...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.clon.2017.02.009

データ提供：米国国立医学図書館（NLM）

Targeted Therapy in Thyroid Cancer: A New Frontier in Treatment

This article discusses the state of the art in targeted therapy for thyroid cancer, highlighting the emergence of tyrosine kinase inhibitors (TKIs) as a promising treatment option for advanced and recurrent cases. The article delves into the molecular mechanisms of TKIs and their role in inhibiting specific signaling pathways involved in cancer cell growth and proliferation. It also reviews the clinical evidence for the efficacy of TKIs in treating various types of thyroid cancer, including differentiated, medullary, poorly differentiated, and anaplastic thyroid cancer.

TKIs: A New Weapon in the Fight Against Thyroid Cancer

This article explores the emergence of tyrosine kinase inhibitors (TKIs) as a powerful weapon in the fight against thyroid cancer. The authors highlight the efficacy of TKIs in treating advanced and recurrent thyroid cancers, offering a potential oasis of hope for patients with this challenging disease. This research showcases the progress made in targeted therapy for thyroid cancer, paving the way for more effective and personalized treatment strategies.

The Future of Thyroid Cancer Treatment: A Personalized Approach

This article emphasizes the future of thyroid cancer treatment, highlighting the importance of personalized medicine and targeted therapies. The emergence of tyrosine kinase inhibitors (TKIs), which specifically target key signaling pathways involved in cancer cell growth, offers a new era of personalized treatment for thyroid cancer. This research underscores the ongoing development of innovative therapies tailored to the individual needs of patients, offering a potential oasis of hope for those battling this disease.

Dr.Camel's Conclusion

This article unveils the potential of targeted therapy in revolutionizing the treatment of thyroid cancer. It’s like discovering a hidden oasis of knowledge in the vast desert of cancer research, offering hope and a more personalized approach to fighting this disease.

Date :
  1. Date Completed 2017-06-26
  2. Date Revised 2022-04-08
Further Info :

Pubmed ID

28318881

DOI: Digital Object Identifier

10.1016/j.clon.2017.02.009

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.